Portal Vein Thrombosis in Adults without Cirrhosis

被引：0
作者：
Wallace F. [1 ]
Simonetto D.A. [2 ]
机构：
[1] Mayo Clinic Internal Medicine, 200 First Street SW, Rochester, 55905, MN
[2] Mayo Clinic Gastroenterology and Hepatology, 200 First Street SW, Rochester, 55905, MN
来源：
Current Hepatology Reports | 2023年 / 22卷 / 4期
关键词：
Extrahepatic portal vein obstruction; Portal cavernoma; Portal cavernoma cholangiopathy; Portal hypertension; Portal vein thrombosis; Splanchnic vein thrombosis;
D O I：
10.1007/s11901-023-00616-5
中图分类号：
学科分类号：
摘要：
Purpose of Review: The management of non-cirrhotic, non-tumoral portal vein thrombosis (PVT) has historically been challenging due to a paucity of data. The purpose of this review is to summarize the recommendations from major society guidelines and to highlight emerging evidence from recent years. Recent Findings: While direct oral anticoagulants are increasingly used for the treatment of non-cirrhotic PVT, prospective comparison with warfarin or low molecular weight heparin remains uninvestigated in this population. There is growing evidence that optimal treatment requires a tailored approach based on the underlying etiology of PVT, with options ranging from a relatively short course of anticoagulation to an aggressive combined medical/procedural approach. Summary: Anticoagulation remains the mainstay of treatment for non-cirrhotic PVT. Current therapies are effective at reducing the risk of both immediate complications and long-term sequelae. Future studies should focus on refining the preferred approach to treatment based on etiology of PVT. © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023.
引用
收藏
页码：244 / 251
页数：7
相关论文
共 40 条
  • [1] Francoz C., Valla D., Durand F., Portal vein thrombosis, cirrhosis, and liver transplantation, J Hepatol, 57, 1, pp. 203-212, (2012)
  • [2] Connolly G.C., Chen R., Hyrien O., Mantry P., Bozorgzadeh A., Abt P., Et al., Incidence, risk factors and consequences of portal vein and systemic thromboses in hepatocellular carcinoma, Thromb Res, 122, 3, pp. 299-306, (2008)
  • [3] Ageno W., Dentali F., Pomero F., Fenoglio L., Squizzato A., Pagani G., Et al., Incidence rates and case fatality rates of portal vein thrombosis and Budd-Chiari Syndrome, Thromb Haemost, 117, 4, pp. 794-800, (2017)
  • [4] Rajani R., Bjornsson E., Bergquist A., Danielsson A., Gustavsson A., Grip O., Et al., The epidemiology and clinical features of portal vein thrombosis: a multicentre study: the epidemiology and clinical features of portal vein thrombosis, Aliment Pharmacol Ther, 32, 9, pp. 1154-1162, (2010)
  • [5] Intagliata N.M., Caldwell S.H., Tripodi A., Diagnosis, development, and treatment of portal vein thrombosis in patients with and without cirrhosis, Gastroenterology, 156, 6, pp. 1582-1599.e1, (2019)
  • [6] Plessier A., Darwish-Murad S., Hernandez-Guerra M., Consigny Y., Fabris F., Trebicka J., Et al., Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study, Hepatology, 51, 1, pp. 210-218, (2010)
  • [7] Simonetto D.A., Singal A.K., Garcia-Tsao G., Caldwell S.H., Ahn J., Kamath P.S., ACG clinical guideline: disorders of the hepatic and mesenteric circulation, Am J Gastroenterol, 115, 1, pp. 18-40, (2020)
  • [8] Lee H.K., Park S.J., Yi B.H., Yeon E.K., Kim J.H., Hong H.S., Portal vein thrombosis: CT features, Abdom Imaging, 33, 1, pp. 72-79, (2008)
  • [9] Elkrief L., Houssel-Debry P., Ackermann O., Franchi-Abella S., Branchereau S., Valla D., Et al., Portal cavernoma or chronic non cirrhotic extrahepatic portal vein obstruction, Clin Res Hepatol Gastroenterol, 44, 4, pp. 491-496, (2020)
  • [10] Northup P.G., Garcia-Pagan J.C., Garcia-Tsao G., Intagliata N.M., Superina R.A., Roberts L.N., Et al., Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the american association for the study of liver diseases, Hepatology, 73, 1, pp. 366-413, (2021)
1234